These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28821236)

  • 1. Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab.
    Gonzalez-Buendia L; Delgado-Tirado S; Sanabria MR; Fernandez I; Coco RM
    BMC Ophthalmol; 2017 Aug; 17(1):147. PubMed ID: 28821236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
    Abdelfattah NS; Al-Sheikh M; Pitetta S; Mousa A; Sadda SR; Wykoff CC;
    Ophthalmology; 2017 Feb; 124(2):215-223. PubMed ID: 27863845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RETICULAR PSEUDODRUSEN ARE NOT A PREDICTIVE FACTOR FOR THE 1-YEAR RESPONSE TO INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Nghiem-Buffet S; Giocanti-Auregan A; Jung C; Dubois L; Dourmad P; Galbadon L; Fajnkuchen F; Quentel G; Cohen SY
    Retina; 2017 Jan; 37(1):53-59. PubMed ID: 27380430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
    Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
    Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choroidal Thickness Changes After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
    Minnella AM; Federici M; Falsini B; Barbano L; Gambini G; Lanza A; Caporossi A; Savastano MC
    BioDrugs; 2016 Aug; 30(4):353-9. PubMed ID: 27189458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.
    Grunwald JE; Pistilli M; Daniel E; Ying GS; Pan W; Jaffe GJ; Toth CA; Hagstrom SA; Maguire MG; Martin DF;
    Ophthalmology; 2017 Jan; 124(1):97-104. PubMed ID: 28079023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project.
    Daien V; Nguyen V; Essex RW; Guymer R; Arnold JJ; Munk M; Ceklic L; Gillies MC; Barthelmes D;
    Br J Ophthalmol; 2020 Aug; 104(8):1064-1069. PubMed ID: 31843790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Daniel E; Pan W; Ying GS; Kim BJ; Grunwald JE; Ferris FL; Jaffe GJ; Toth CA; Martin DF; Fine SL; Maguire MG;
    Ophthalmology; 2018 Jul; 125(7):1037-1046. PubMed ID: 29454660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics that Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration.
    Staurenghi G; Cozzi M; Sadda S; Hill L; Gune S
    Ophthalmol Retina; 2023 Apr; 7(4):300-306. PubMed ID: 36372347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes.
    Channa R; Sophie R; Bagheri S; Shah SM; Wang J; Adeyemo O; Sodhi A; Wenick A; Ying HS; Campochiaro PA
    Am J Ophthalmol; 2015 Jan; 159(1):9-19.e1-2. PubMed ID: 25217857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oct parameters as predictive factors for the visual outcome after ranibizumab therapy in neovascular age related macular degeneration].
    Valverde-Megías A; Donate-López J; García-Gil-de-Bernabé J; Megías-Fresno A; García-Feijoo J
    Arch Soc Esp Oftalmol; 2015 Apr; 90(4):156-63. PubMed ID: 25620678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Outcomes in Patients with Neovascular Age-Related Macular Degeneration Who Maintain Dry Macula after Three Monthly Ranibizumab Injections.
    Kim KM; Kim JH; Chang YS; Kim JW; Kim CG
    Semin Ophthalmol; 2018; 33(3):371-376. PubMed ID: 27960586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain.
    Coco RM; Sanabria MR; Castrejon M; Lopez-Galvez MI; Monje-Fernandez L; Fernandez-Munoz M; Anton A; de Juan-Marcos L; Villaron-Alvarez S; Fernandez I
    BMC Ophthalmol; 2014 Nov; 14():138. PubMed ID: 25416399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision.
    Shona O; Gupta B; Vemala R; Sivaprasad S
    Clin Exp Ophthalmol; 2011 Jan; 39(1):5-8. PubMed ID: 21040311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.